ESEnrico Selvi

Enrico Selvi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Enrico Selvi has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 31 August 2010
      • Vol. 28  (4) , 591

    False proteinuria in patients with alkaptonuria.

    by E Selvi, E Garcia-Gonzalez, R Maggio, S Lorenzini, A Santucci, M Galeazzi


    • 15 December 2007
      • Vol. 25  (5) , 696-700

    Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1beta-stimulated synoviocytes from rheumatoid arthritis patients.

    by P E Lazzerini, S Lorenzini, E Selvi, P L Capecchi, D Chindamo, S Bisogno, R Ghittoni, M R Natale, F Caporali, S Giuntini, et al.

    Recent studies demonstrated in vivo the effectiveness of statins in reducing the inflammatory response in rheumatic diseases, and still more recently, simvastatin has been reported to inhibit in vitro IL-6 and IL-8 production by unstimulated fibroblast-like-synoviocytes (FLS) from rheumatoid arthritis (RA) patients. However, no data are available on the effect of statins on the production of these cytokines induced by IL-1, which plays a crucial role in joint inflammation in the course of active RA in vivo. In 12 RA patients, synovial tissue specimens were taken to obtain cultures of FLS. Cultures were incubated with IL-1 +/- simvastatin (5-50 micromol/l), and IL-6 and IL-8 production was evaluated (ELISA), also following the addition of mevalonate and its isoprenoid derivatives. Moreover, nuclear factor-kB (NF-kB) activation (immunocytochemistry and Western Blot analysis) were also evaluated. Culture incubation with IL-1 produced a dramatic increase (up to 40-fold) in cytokine production with respect to unstimulated cells. Simvastatin significantly inhibited (about 20%) IL-6 and IL-8 production from IL-1-stimulated FLS. This effect was completely reverted by the concomitant incubation with mevalonate or geranylgeraniol (but not farnesol or squalene). Moreover, simvastatin produced a clear-cut inhibition of IL-1-induced NF-kB activation. Simvastatin significantly inhibits the production of IL-6 and IL-8 also in IL-1-stimulated FLS, even though to a lesser extent than in unstimulated cells, via a HMG-CoA-reductase block with an interference in prenylation process and NF-kB activation. Our results further support the rationale for the use of statins in the treatment of rheumatoid synovitis.


    • 8 September 2006
      • Vol. 24  (4) , 387-93

    Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients.

    by P E Lazzerini, E Selvi, S Lorenzini, P L Capecchi, R Ghittoni, S Bisogno, M Catenaccio, R Marcolongo, M Galeazzi, F Laghi-Pasini

    Hyperhomocysteinemia is commonly observed in Rheumatoid Arthritis (RA) patients, thus putatively accounting in part for the high rate of cardiovascular events in these subjects. Homocysteine (Hcy) is known to exert a pro-inflammatory effect putatively contributing to the progression of atherosclerotic lesions by cytokine production from several vascular cell-types. In order to evaluate the possibility that Hcy may play a direct pro-inflammatory activity also in the joints of RA patients, we investigated: (i) the joint concentration of Hcy, and (ii) the effect of Hcy on cytokine production by unstimulated and IL-1beta-stimulated human RA cultured synoviocytes. In 5 RA and 5 controls subjects, Hcy was measured in the blood and knee synovial fluid, and specimens of synovial tissue were taken to obtain cell cultures. Cultures were incubated with Hcy (10-100 micromol/l) +/- IL-1beta, and IL-6 and IL-8 concentrations were evaluated in the supernatants (ELISA) together with the activation of nuclear factor-kB (NF-kB) (immunocytochemistry). Hcy was present in synovial fluids, with a mean concentration significantly higher in RA patients than in controls (9.0 +/- 1.1 vs 5.9 +/- 1.2 micromol/l). Hcy enhanced IL-6 and IL-8 production in RA synoviocytes only (up to 35%). Moreover, Hcy produced a clear-cut activation of NF-kB in rheumatoid cells only. Hcy enhances IL-1-dependent cytokine production by rheumatoid synoviocytes at a concentration measurable in RA joints in vivo. Thus, in RA patients, Hcy may not only represent an important risk factor for the progression of cardiovascular diseases, but it may also contribute to the joint damage.


  • Combination Therapy With Montelukast and Ketotifen for Arthritis and Rash Resulting From Idiopathic Hypereosinophilic Syndrome

    by Enrico Selvi, Pietro Rubegni, Stefania Manganelli, Renato De Stefano, Elena Frati, Sauro Bsc Lorenzini, Paolo Sbano, Roberto Marcolongo

    Idiopathic hypereosinophilic syndrome (IHES) is a rare condition of uncertain etiology characterized by marked peripheral blood eosinophilia and organ system dysfunction that cannot be explained by any factor other than the presence of eosinophils or their potentially toxic products. Diagnostic criteria include 1) a sustained eosinophilia greater than 1500/mm3 for longer than 6 months, 2) absence of other causes of eosinophilia, including parasitic infections and allergic diseases, and 3) multiorgan involvement (ie, lungs, heart, central nervous system, skin, liver, joints). Steroids represent the initial therapeutic approach, although for those patients unresponsive to steroids, cytotoxic chemotherapy should be considered. We describe a case of IHES characterized by polyarticular inflammatory joint involvement, hypereosinophilia, and urticarioid skin manifestations without visceral involvement. Synovial fluid smears as well as pathology of skin lesions and knee synovial membrane confirmed the presence of numerous eosinophils. The patient was successfully treated with a combination therapy of a cysteinyl leukotriene receptor antagonist (montelukast) and ketotifen. Hypereosinophilic syndrome like in this patient is a rare cause of polyarthritis.


    • 1 March 2004
      • Vol. 31  (3) , 622

    Arthritis induced by corticosteroid crystals.

    by Enrico Selvi, Renato De Stefano, Sauro Lorenzini, Roberto Marcolongo


    • 16 May 2003
      • Vol. 21  (2) , 269

    N-acetylcysteine and vitamin E: an in vitro study of their effect on homogentisic acid polymerization.

    by D Chindamo, M Catenaccio, S Lorenzini, E Selvi, M Molinelli, G Cavallo, R Marcolongo


  • Open Access

    Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis

    by E Selvi, S A Tripodi, M Catenaccio, S Lorenzini, D Chindamo, S Manganelli, R Romagnoli, F Ietta, L Paulesu, C Miracco, et al.

    Objective: To evaluate whether, in patients with the diffuse form of systemic sclerosis (dSSc), macrophage migration inhibitory factor (MIF) production is dysregulated. Methods: 10 patients with dSSc and 10 healthy controls, matched for age and sex, were studied. MIF expression was evaluated by immunohistochemistry on formalin fixed skin biopsies of patients with dSSc and controls. MIF levels were assayed in the sera and in the supernatants of skin cultured fibroblasts by a colorimetric sandwich enzyme linked immunosorbent assay (ELISA). MIF concentrations in culture medium samples and in serum samples were compared by Student’s two tailed t test for unpaired data. Results: Anti-MIF antibody immunostained the basal and mainly suprabasal keratinocytes. Small perivascular clusters of infiltrating mononuclear cells were positive; scattered spindle fibroblast-like cells were immunostained in superficial and deep dermal layers. The serum concentrations of MIF in patients with dSSc (mean (SD) 10705.6 (9311) pg/ml) were significantly higher than in controls (2157.5 (1288.6) pg/ml; p=0.011); MIF levels from dSSc fibroblast cultures (mean (SD) 1.74 (0.16) ng/2×105 cells) were also significantly higher than in controls (0.6 (0.2) ng/2×105 cells; p=0.008). Conclusion: These results suggest that MIF may be involved in the amplifying proinflammatory loop leading to scleroderma tissue remodelling.


  • Open Access

    Kaposi's sarcoma in psoriatic arthritis

    by E. Selvi, R. De Stefano, S. Manganelli, R. Marcolongo

    Sir, We read with great interest the case report by Burnet and McNeil [1], which describes the onset of Kaposi's sarcoma (KS) in a patient with rheumatoid arthritis following an intra‐articular corticosteroid injection. To date, iatrogenic KS is considered an unusual, although recognized complication of immunosuppressive therapy, including steroid treatment [2–4]. However, in rheumatological clinical practice it is very rare for patients to develop such a complication in spite of the large number of patients who receive immunosuppressive therapy. This observation supports the hypothesis that the development of KS may require further ethnic, geographical, genetic or environmental predisposing factors, such as infectious agents [5]. Here we report an additional case of KS in an elderly female patient with a history of long‐standing destructive psoriatic arthritis (PsA). The patient, aged 75 yr, had been affected by PsA for approximately 30 yr. In previous years she had been treated with topical steroids, keratolytic agents and non‐steroidal anti‐inflammatory agents (NSAIDs); in 1995 she had also received a short course of low‐dose i.m. methotrexate, which was subsequently withdrawn because of liver toxicity. From 1996 onwards, she had been taking sulphasalazine (2 g daily) and 6‐methylprednisolone (4 mg i.m.) with moderate improvement of the arthritis. In December 1996 the patient developed progressively enlarging purple nodules on the left forefoot, followed by similar skin lesions on the scalp, shins and forearms. KS was diagnosed on the basis of the typical histopathological changes found in a skin sample obtained by excision biopsy. Corticosteroids were stopped, and treatment with argon laser photocoagulation was commenced. The treatment proved partially effective. In 2001, the patient was admitted to our clinic complaining of a flare of polyarticular joint pain and swelling affecting the wrists, hands, shoulders and knees. Physical examination revealed swelling of the knees and wrists, diffuse psoriatic plaques, and multiple, widespread nodular purplish lesions, some of which were ulcerating. At that time, the patient was taking only sulphasalazine and NSAIDs, but not steroids, apart from the odd intra‐articular triamcinolone acetonide injection. Histological examination of a biopsy specimen from a leg nodule confirmed the diagnosis of KS. Laboratory data showed only markedly increased acute‐phase reactants and mild anaemia (haemoglobin 11 g/dl). Serological screening for infectious agents, including HIV and herpesvirus 8, was negative; extensive imaging studies were unremarkable apart from the findings related to the underlying arthropathy. The patient did not consent to receiving specific treatment for KS.


    • 1 May 2001
      • Vol. 28  (5) , 1112-3

    A cholesterol "ganglion".

    by E Selvi, M Hammoud, R De Stefano, M R Cicero, R Marcolongo

  • Open Access

    Diff Quik staining method for detection and identification of monosodium urate and calcium pyrophosphate crystals in synovial fluids

    by E Selvi, S Manganelli, M Catenaccio, R De Stefano, E Frati, S Cucini, R Marcolongo

    OBJECTIVE To evaluate whether the Diff Quik (DQ) staining method might prove useful in identifying monosodium urate (MSU) and calcium pyrophosphate dihydrate (CPPD) crystals on permanent mounted stained slides. METHODS 27 synovial fluid (SF) samples obtained from the knees of 21 patients with acute CPPD disease and 6 with acute gout were studied. Wet analysis for crystal detection and identification was performed within one hour of joint aspiration. In addition, 16 inflammatory synovial effusions obtained from patients with knee arthritis induced by non-crystalline inflammatory diseases were studied. For each SF, a DQ stained slide was analysed by two of the authors trained in SF analysis. The observers were blinded to the type of crystals present in the SF. Each slide was analysed by compensated polarised as well as transmitted light microscopy. An SF was considered positive if intracellular and/or extracellular crystals were clearly identified. In addition, the observer was asked to identify the type of the crystals using compensated polarised light microscopy. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of the DQ staining method were determined. RESULTS 51 true positive and 28 true negative cases were correctly classified (39 CPPD samples, 12 MSU samples, 28 samples of crystal unrelated arthropathies). Overall, four false positive and three false negative cases were reported. In all the false positive cases, extracellular CPPD crystals were erroneously identified, whereas CPPD crystals present in the SF were not identified in the three false negative cases. All MSU specimens were correctly diagnosed. The overall specificity, sensitivity, and accuracy using DQ stained slides for crystal confirmation were respectively 87.5%, 94.4%, and 91.9%. The PPV was 92.7% and the NPV 90.3%. In particular, the specificity, sensitivity, and accuracy for CPPD detection were 90.9%, 92.9%, and 91.9%, with a PPV of 90.7 and an NPV of 93.0%. All the MSU specimens were correctly identified, providing 100% sensitivity, specificity, accuracy, PPV, and NPV. CONCLUSIONS Stained preparations of SF, including DQ stained smears, could provide a useful tool for delayed SF analysis suitable for quality controls, including cytological examination and crystals detection and identification.